Sconry Biopharma (Shanghai) Co., Ltd.  is a biotechnology company centered on synthetic biology. The company adheres to the philosophy of ”Creation from nature, derived from nature, applied to nature,“ focusing on ”engineering“ and ”industrialization“ to drive green science and value creation in the fields of medicine, healthcare, agriculture, and animal protection.

Core Business:

Products: NAD+, 5-ALA, Arecoline, Danshensu, γ-Aminobutyric acid, Sodium heparin, Calcium propionate, FDCA, etc.

Production process development and technical services: Target customers include traditional fine chemical production companies and synthetic biology companies.

Founded in June 2022, the founding team has known each other for many years, bringing together talent from various fields such as synthetic biology research and development, production, and marketing. All team members have extensive experience in the design, research, development, production, and sales of biotech companies. Based on the team's years of research achievements and innovative platform, the company has completed the R&D and mass production of several products. Sconry Biopharma possesses a unique innovative R&D and production system based on synthetic biology.

Technical Uniqueness: ”Reverse“ gene modification and a glycolysis enzyme library solidify the foundation of biological creation and modification.

Industry Leadership: Achieving near-zero enzyme catalysis costs, with production output and industrial scale far surpassing industry peers, leading to significantly reduced unit costs.